BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25430497)

  • 1. Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial.
    Kapp JR; Diss T; Spicer J; Gandy M; Schrijver I; Jennings LJ; Li MM; Tsongalis GJ; de Castro DG; Bridge JA; Wallace A; Deignan JL; Hing S; Butler R; Verghese E; Latham GJ; Hamoudi RA
    J Clin Pathol; 2015 Feb; 68(2):111-8. PubMed ID: 25430497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.
    Deans ZC; Bilbe N; O'Sullivan B; Lazarou LP; de Castro DG; Parry S; Dodson A; Taniere P; Clark C; Butler R
    J Clin Pathol; 2013 Apr; 66(4):319-25. PubMed ID: 23378269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.
    Do H; Dobrovic A
    Oncotarget; 2012 May; 3(5):546-58. PubMed ID: 22643842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA qualification workflow for next generation sequencing of histopathological samples.
    Simbolo M; Gottardi M; Corbo V; Fassan M; Mafficini A; Malpeli G; Lawlor RT; Scarpa A
    PLoS One; 2013; 8(6):e62692. PubMed ID: 23762227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.
    Didelot A; Le Corre D; Luscan A; Cazes A; Pallier K; Emile JF; Laurent-Puig P; Blons H
    Exp Mol Pathol; 2012 Jun; 92(3):275-80. PubMed ID: 22426079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized fixation process is crucial to permit molecular analyses in formalin-fixed and paraffin-embedded melanoma samples.
    Uguen A; Guibourg B; Guéguen P
    Clin Chem Lab Med; 2016 Nov; 54(11):e359-e360. PubMed ID: 27289004
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens.
    Gallegos Ruiz MI; Floor K; Rijmen F; Grünberg K; Rodriguez JA; Giaccone G
    Cell Oncol; 2007; 29(3):257-64. PubMed ID: 17452778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
    Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
    Kitano S; Myers J; Nakamura J; Yamane A; Yamashita M; Nakayama M; Tsukahara Y; Ushida H; Liu W; Ratain MJ; Amano M
    PLoS One; 2013; 8(5):e62989. PubMed ID: 23671647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples.
    Bhagwate AV; Liu Y; Winham SJ; McDonough SJ; Stallings-Mann ML; Heinzen EP; Davila JI; Vierkant RA; Hoskin TL; Frost M; Carter JM; Radisky DC; Cunningham JM; Degnim AC; Wang C
    BMC Genomics; 2019 Sep; 20(1):689. PubMed ID: 31477010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
    Potrony M; Badenas C; Naerhuyzen B; Aguilera P; Puig-Butille JA; Tell-Marti G; Díaz A; Carrera C; Alos L; Delahaye N; Malvehy J; Puig S
    Clin Chem Lab Med; 2016 Nov; 54(11):1733-1738. PubMed ID: 27101548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.
    Vacca D; Cancila V; Gulino A; Lo Bosco G; Belmonte B; Di Napoli A; Florena AM; Tripodo C; Arancio W
    Mol Biol Rep; 2018 Feb; 45(1):1-7. PubMed ID: 29238890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative Tumor Tissue Dissection Tool for Molecular Oncology Diagnostics.
    Javey M; Reinsch C; Feldkamp M; Siemann S; Blüher A; Woestmann C; Cai L; Tran I; May T; Havnar C; Lo AA; Hinzmann B; Heilek G; Palma JF
    J Mol Diagn; 2021 Apr; 23(4):399-406. PubMed ID: 33497835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.